FDA Expands TearCare Indication to First Treatment Improving Meibomian Gland Function
Event summary
- FDA updated TearCare's indication on August 18, 2026 to include improvement of meibomian gland function in evaporative dry eye disease due to MGD.
- TearCare becomes the first and only treatment with this specific indication.
- The update incorporates optional debridement as part of the TearCare System.
- Sight Sciences positions TearCare as addressing the underlying cause of dry eye disease rather than just symptoms.
The big picture
This FDA decision validates a shift in dry eye treatment toward addressing physiological function rather than symptom management. Sight Sciences positions itself at the forefront of interventional dry eye care, potentially reshaping the competitive landscape. The approval underscores the growing emphasis on treating underlying causes of chronic eye diseases, aligning with broader trends in ophthalmology toward more targeted, functional therapies.
What we're watching
- Market Adoption
- How quickly eye care providers will integrate TearCare into their treatment protocols for MGD patients.
- Competitive Response
- Whether existing dry eye treatments will need to evolve or differentiate in response to TearCare's expanded indication.
- Reimbursement Dynamics
- The pace at which payers will recognize and reimburse TearCare under its new indication.